Clinical trials: Asthma
Respiratory Disorders, Asthma and Rhinitis
Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions
This study is conducted to determine whether the test product (GW483100 10 mg containing montelukast sodium equivalent to 10 mg of montelukast) is bioequivalent to the reference montelukast sodium 10 mg tablets (innovator…
- Trial name
- NCT02658422
- Testing
- Test Montelukast, Reference Montelukast
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Asthma
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.
- Trial name
- NCT01310322
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Roflumilast Plus Montelukast in Adults With Severe Asthma
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
- Trial name
- NCT01765192
- Testing
- Roflumilast, Montelukast
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Asthma
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
- Trial name
- BORA (NCT02258542)
- Testing
- Benralizumab
- Where
- 429 sites in United States, Argentina and 22 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Asthma
Clinical Study to Evaluate Z7200 Pharmacokinetics Profile
Brief Summary: The primary objective was: to assess the bioequivalence of a single dose (two inhalations) of the test product compared to the reference product, with and without charcoal blockade.
- Trial name
- NCT02631941
- Testing
- Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler
This study aims to explore the potential impact of switching inhalers by assessing the handling error rate (critical and non-critical) in controlled asthmatics currently treated with, and using correctly, SERETIDE via the DISKUS…
- Trial name
- NCT02416180
- Testing
- SERETIDE MDI
- Where
- 7 sites in Germany
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.
- Trial name
- COMPAIR (NCT07433569)
- Testing
- Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Asthma
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional participant reported sleep outcomes To evaluate the effect of dupilumab on objective sleep…
- Trial name
- MORPHEO (NCT04502862)
- Testing
- SAR231893
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 202 people
- Sponsor
- Sanofi
Asthma
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved…
- Trial name
- NCT06502366
- Testing
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg
- Where
- 128 sites in United States, China and 4 more
- Volunteers
- 424 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis, Asthma
Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Grass-SPIRE to subjects suffering from both grass allergy and asthma
- Trial name
- NCT02161107
- Testing
- Grass-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 54 people
- Sponsor
- Circassia Limited
Persistent Asthma
Impact of Lung Flute Therapy on Asthma
We hypothesized that the ability of the Lung Flute to enhance mucus clearance from the lower airways could be used to improve asthma control, if the device is used on a chronic basis.
- Trial name
- NCT02003521
- Testing
- Lung Flute
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Medical Acoustics LLC
Allergic Asthma
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)
The primary purpose of this study is to examine whether the geometric mean of serum free IgE level at 24 weeks of the treatment period in Japanese pediatric patients (6 to 15 years of age) reaches under 25 ng/mL (target level).
- Trial name
- NCT01155700
- Testing
- omalizumab
- Where
- 17 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Asthma Control Level
Assessment of Asthma Control Level in Primary Care Setting in Malaysia
A prospective observational multi center study to assess the level of asthma control at Primary Care Setting; government health clinics (Klinik Kesihatan) in Malaysia.
- Trial name
- ASCOPE (NCT03804632)
- Where
- 10 sites in Malaysia
- Volunteers
- 1,011 people
- Sponsor
- AstraZeneca
Asthma
A Study of MK0359 in Patients With Chronic Asthma (0359-013)
A study to test the effect of MK0359 in lessening the symptoms of asthma as compared to placebo.
- Trial name
- NCT00482898
- Testing
- MK0359
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China
The primary objective of the NIS is to evaluate the severity of newly diagnosed asthma patients based on Global Initiative for Asthma (GINA) severity category (GINA 2006 update).
- Trial name
- INITIAL (NCT02143739)
- Where
- 30 sites in China
- Volunteers
- 4,817 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test
A multicenter, open-label study to evaluate the sensitivity and specificity of inhaled methacholine in bronchial provocation test
- Trial name
- NCT05634473
- Testing
- Methacholine Chloride
- Where
- 12 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
Study of MAP0010 in Asthmatic Children and Adolescents
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
- Trial name
- NCT00697801
- Testing
- MAP0010 low dose, MAP0010 high dose
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Allergan
Asthma
A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)
A study to determine the efficacy of MK0476 in the Treatment of Asthmatic Patients Aged 2 to 5 Years.
- Trial name
- NCT00700661
- Testing
- montelukast
- Volunteers
- 500 people
- Sponsor
- Organon and Co
Asthma, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
- Conditions
- Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00862641
- Testing
- Regadenoson
- Where
- 48 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Astellas Pharma Inc